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Abstract The heterologous expression of genes or gene clus-
ters in microbial hosts, followed by metabolic engineering of
biosynthetic pathways, is key to access industrially and phar-
maceutically relevant compounds in an economically afford-
able and sustainable manner. Therefore, platforms need to be
developed, which provide tools for the controlled synthesis of
bioactive compounds. The Gram-positive bacterium Bacillus
subtilis is a promising candidate for such applications, as it is
generally regarded as a safe production host, its physiology is
well investigated and a variety of tools is available for its
genetic manipulation. Furthermore, this industrially relevant
bacterium provides a high secretory potential not only for
enzymes but also for primary and secondary metabolites. In
this study, we present the first heterologous expression of an
eukaryotic non-ribosomal peptide synthetase gene (esyn) cod-
ing for the biosynthesis of the small molecule enniatin in
B. subti l is . Enniatin is a pharmaceutical ly used
cyclodepsipeptide for treatment of topical bacterial and fungal
infections. We generated various enniatin-producing
B. subtilis strains, allowing for either single chromosomal or
plasmid-based multi-copy expression of the esyn cluster under
the control of an acetoin-inducible promoter system.
Optimization of cultivation conditions, combined with
modifications of the genetic background and multi-copy plas-
mid-based esyn expression, resulted in a secretory production
of enniatin B. This work presents B. subtilis as a suitable host
for the expression of heterologous eukaryotic non-ribosomal
peptide synthetases (NRPS) clusters.
Keywords Heterologous expression . Iterative NRPS .
Cyclodepsipeptide . acoA promoter . Acetoin .Metabolic
engineering
Introduction
There is an increasing demand for new bioactive natural
products, which can in many cases not be covered from
natural sources (Koehn and Carter 2005). Hence, quite often,
the development of fermentation processes using suitable
heterologous hosts is necessary. In addition, there are many
safety requirements for the industrial production of enzymes
and drugs (especially for food and pharmaceutical products)
which are regulated and controlled by the Food and Drug
Administration (FDA) or the European Medicine Agency
(EMA).
Bacillus subtilis, a Gram-positive, non-pathogenic strain
with a generally recognized as safe (GRAS) status and qual-
ified presumption of safety (QPS) certification can fulfil these
requirements (Leuschner et al. 2010; Sietske de Boer and
Diderichsen 1991). Unlike Gram-negative hosts such as
Escherichia coli, which feature lipopolysaccharides on the
outer cell membrane, B. subtilis lacks these endotoxins, which
simplifies downstream processing (Petsch and Anspach
2000). Furthermore, using B. subtilis as an expression host is
advantageous due to its natural ability to secrete peptides into
the environment, e.g. to interact with plants or pathogens
(Mongkolthanaruk 2012). It is especially noteworthy that
B. subtilis, in contrast to E. coli, is a more prolific natural
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producer of various bioactive compounds originating from
non-ribosomal peptide synthetases (NRPS) and polyketide
synthases (PKS) (Stein 2005). These include the non-
ribosomally synthesized lipopeptides surfactin (Arima et al.
1968; Nakano et al. 1991) and plipastatin showing antimicro-
bial activity (Tsuge et al. 2007), as well as the PKS/NRPS-
hybrid molecule bacillaene with antibacterial effects (Butcher
et al. 2007; Chen et al. 2007; Patel et al. 1995). In addition,
B. subtilis was already successfully used as surrogate host for
the engineered biosynthesis of the peptide antibiotic bacitracin
from Bacillus licheniformis (Eppelmann et al. 2001). For the
above reasons, B. subtilis is virtually predestined for heterol-
ogous NRPS production.
In this study, the NRPS-derived cyclohexadepsipeptide
enniatin was used (Fig. 1), which is produced in a non-
ribosomal fashion by various filamentous fungi such as
Fusarium and Verticillium species (Süssmuth et al. 2011).
These filamentous fungi are characterized by long fermenta-
tion times and are nearly insusceptible to standard procedures
of genetic manipulations for production level enhancement or
pathway engineering. Enniatin is well-known for a broad
range of bioactivities, and it shows various antibacterial, in-
secticidal, antifungal, herbicidal, anthelmintic and anticancer
activities (Dornetshuber et al. 2007; Kamyar et al. 2004;
Kleinkauf and von Döhren 1990; Kouri et al. 2003; Pleiss
et al. 1996; Süssmuth et al. 2011).
To date, 29 natural enniatin derivatives are known, which
differ in their amino acid and α-hydroxy-carboxylic acid
composition. A mixture of enniatin A, B and C finds applica-
tion as fusafungin (Locabiosol®), a drug for treatment of
upper respiratory tract infections (URTI) which shows bacte-
riostatic and anti-inflammatory properties against several mi-
croorganisms involved in superinfections, like Streptococcus
pneumoniae, Staphylococcus aureus, Haemophilus influenzae
and Candida albicans (German-Fattal 1988; Karam-Sarkis
et al. 1991; Lund et al. 2004).
Enniatin is synthesized by the enniatin synthetase (ESYN),
a non-ribosomal peptide synthetase which assembles the
hexadepsipeptide in an iterative manner. The 347-kDa multi-
enzyme complex consists of two modules. Each module pro-
vides a functional unit involving a condensation (C) domain,
an adenylation (A) domain and a peptidyl carrier protein
(PCP) domain (Glinski et al. 2002; Pieper et al. 1995). The
A domains recognize their L-configured amino acid and D-α-
hydroxy carboxylic acid substrate and activate them in an
ATP-dependent manner by adenylation at the carboxy group
to yield acyl monoadenylates. The activated substrates are
then transferred to a PCP domain, posttranslationally modified
with a CoA arm, which is the acceptor for thiolation with the
substrate. This PCP domain is phosphopantheteinylated by a
phosphopantetheine transferase (PPTase). Intermediates that
are covalently bound to the phosphopantetheine prosthetic
group of the PCP domain are subsequently presented to
the C domain, located upstream or downstream, responsi-
ble for the formation of the corresponding ester or amide
bond between two activated substrates (Billich and Zocher
1988). An intermediate step is N-methylation of the L-
amino acid by a methylation domain (MT domain).
Emerging dipeptidoles are then temporarily stored at a
so-called waiting position operated by a third PCP domain
until the next dipeptidole subunit is formed and can be
loaded onto the last PCP domain forming a 4-mer
peptidole (Süssmuth et al. 2011). Upon availability of
the third and last dipeptidole, the synthesis is completed
by a last condensation and a final cyclisation step which
takes place to release the active cyclohexadepsipeptide.
In this work, we established the first heterologous expres-
sion of a fungal non-ribosomal peptide synthetase and syn-
thesis of the corresponding peptide enniatin in B. subtilis. In
this study, the esyn gene encoding the enniatin synthetase
(ESYN) from Fusarium oxysporum (Zocher et al. 1982) was
used as a model for the heterologous expression of a NRPS
cluster in B. subtilis under control of a glucose-repressed and
acetoin-inducible promoter system (Ali et al. 2001; Kabisch
et al. 2013b; Silbersack et al. 2006). In order to optimize the
enniatin production in this host, several cultivation conditions
Fig. 1 Heterologous expression of enniatin in B. subtilis. a Integrative
copy of esyn into the genome or a high-copy plasmid under the control of
an acetoin-inducible promoter (acoA) combined with feeding of D-Hiv
facilitates synthesis of enniatin. Enniatin is synthesized non-ribosomally
by the ATP-dependent non-ribosomal peptide synthetase enniatin
synthetase (ESYN). b Structure of the cyclohexadepsipeptide enniatin
composed of alternating D-hydroxyisovalerate (D-Hiv) and L-N-methyl-
valine (L-N-Me-Val). The cyclic peptide is naturally produced by fila-
mentous fungi of Fusarium spec
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and the deletion of potential competing gene clusters for
native secondary metabolites were addressed.
Materials and methods
Cloning
Unless stated otherwise, all chemicals were purchased from
Roth (Karlsruhe, Germany) at the highest purity available and
were used without further purification. B. subtilis 168 (NCBI
AL009126) was used as model production strain in this study.
All cloning procedures were carried out in E. coli DH10B
(Invitrogen, Darmstadt, Germany) [F-endA1 recA1 galE15
galK16 nupG rpsL ΔlacX74 Φ80lacZΔM15 araD139
Δ(ara, leu)7697 mcrAΔ(mrr-hsdRMS-mcrBC) λ-]. All plas-
mids used in this study are listed in Table 1. All strains used
and constructed in this study are summarized in Table 2.
Restriction enzymes and other DNA-modifying enzymes
were used as specified by the supplier (New England
Biolabs, Frankfurt, Germany). Oligonucleotides (Table S1)
were synthesized and provided by Life Technologies
(Darmstadt, Germany). PCR products were purified with the
High Pure PCR Product Purification Kit (Roche, Mannheim,
Germany). Plasmid isolation was performed using the High
Pure Plasmid Isolation Kit (Roche,Mannheim, Germany). For
gel extraction, the QIAquick Gel Extraction Kit from Qiagen
(Hilden, Germany) was used. Recombinant B. subtilis strains
were verified by colony PCR as previously described
(Kumpfmüller et al. 2013). All plasmid constructs and chro-
mosomal integrations (s. supporting online material) were
verified by sequencing carried out by Eurofins Genomics
(Ebersberg, Germany).
Media and cultivation
For the cultivation of B. subtilis strains, a 20-mL pre-culture
was inoculated with a cryo-culture in LB medium (10 g/L
tryptone, 5 g/L yeast extract, 5 g/L NaCl) supplemented with
the corresponding antibiotic. After incubation for 16 h at
37 °C in 50 mL super broth (SB) medium (containing 95 %
solution 1 buffered with 5 % of solution 2; solution 1: 32 g/L
tryptone, 20 g/L yeast extract, 5 g/L NaCl, pH 7; solution 2:
12 g/L Na2HPO4, 6 g/L KH2PO4, 6 g/L NH4Cl, 6 mg/L
CaCl2, pH 7), a second pre-culture was inoculated with
1:100 (v/v) and 0.1 % acetoin (v/v) together with antibiotics
and incubated at 37 °C to optical density at 600 nm
(OD600 nm)=1.0. For the main culture, 100-mL shaking flasks
with three baffles were used containing 20 mL of SB medium
supplemented with antibiotics and 0.1 % acetoin (v/v). The
medium was inoculated at OD600 nm=0.1 and incubated for
1.5 h at 37 °C to reach the exponential phase at OD600 nm=0.6.
Subsequently, the cultures were fed with appropriate
concentrations of 5 mM D-Hiv and incubated at 18 °C for
48 h under shaking conditions with 200 rpm.
Extraction
After cultivation and harvesting of cells from 20-mL cultures,
the supernatant was extracted with an equal volume of ethyl
acetate and agitated for 1 h at room temperature. The cell
pellet was extracted with 5 mL methanol and sonicated for
5 min. After centrifugation, the solvent was removed and
evaporated under vacuum. For mass spectrometric analysis,
the extracts were dissolved in 200 μL HPLC-grade MeOH.
HPLC-ESI-mass spectrometry
All measurements for the analysis of crude extracts of pellet
and supernatant were performed using an Agilent UHPLC
1290 Infinity-Series system containing an Eclipse Plus C18
column (2.1×50 mm) coupled to an ESI-Triple-Quadrupol
mass spectrometer (6460 Series, Agilent Technologies,
Waldbronn, Germany). For chromatographic separation, a
mobile phase H2O (solvent A)/ACN (solvent B) each with
0.1 % formic acid (v/v) was used. The gradient started at 5 %
solvent B to reach 100 % in 4 min and was held constant for
3 min at 100 % solvent B. For MS scan, MS2 and multiple
reaction monitoring (MRM) analysis of enniatin with an exact
mass [M]=639.4095 Da, all measurements were performed in
the positive mode. The three most abundant fragments of MS2
experiments were used for quantification in MRM by frag-
mentation of precursor ion m/z 640 as well the characteristic
mass transitionsm/z 527.4 as quantifier andm/z 427.3 andm/z
196.2 as qualifier ion. For relative quantification, we used a
calibration curve of enniatin B and integrated the measured
peak areas accordingly. Calibration curves comprising five
concentrations in the range of 0.586-9.375 μg/mL were mea-
sured before and after the measurements of enniatin B from
B. subtilis extracts (Fig. S1).
Software
Graphs were created using the graphical and statistical pro-
gram R with the ggplot2 package (Wickham 2009). For box
plots, the whiskers extend from the hinge to the highest and
lowest value, respectively, that is within 1.5×IQR of the
hinge, where IQR is the inter-quartile range. Data beyond
the end of the whiskers are outliers and plotted as points.
Results
Codon usage may exert an influence on gene expression
(Nocon et al. 2014; Samant et al. 2014). Therefore, we first
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performed a bioinformatics analysis of the esyn gene. A
comparison of the codon usage of the F. oxysporum esyn
sequence with the average codon usage of dedicated host
B. subtilis 168 showed a mean deviation of about 35 %
(Codon Usage Database, Kazusa; graphical codon usage
analyser, Fig. S2). This analysis indicates that there is no
significant codon bias which could influence the esyn expres-
sion in B. subtilis.
The plasmid construction for the chromosomal integration
of the esyn gene, encoding the enniatin synthetase, was done
via a modified protocol using the Red/ET recombination
system (Zhang et al. 1998). Due to this method that is based
on a crossover step between a targeting vector containing
homologous regions and the target sequence (fosmid F9D10
carrying the natural esyn gene), amplification of the entire
coding sequence (approx. 10 kb) was not necessary. The
resulting plasmid was designated pJK166. A detailed descrip-
tion of all plasmid and strain constructions can be found in the
supplementary material.
The plasmid pJK166 was used to chromosomally integrate
the esyn gene cluster under control of the acoA promoter into
the amyE locus of B. subtilis JK3. This integration event was
confirmed by colony PCR and an amylase-negative pheno-
type. Finally, one of the positive clones was chosen for marker
removal (resulting in B. subtilis SZ2) followed by chromo-
somal integration of an intact sfp gene by using the pJK64
Table 1 Plasmids used in this study
Plasmid Function Reference
Fosmid F9D10 Fosmid carrying wild-type esyn gene cluster Fosmid library of F. oxysporum ETH 1536,
ESyn ACCN KP000028
pAMY-Kan Backbone for srfA deletion plasmid with KanR Kumpfmüller, unpublished results
pAMY-lox-SSS Integration of genes into the amyE locus with lox-SSS-cassette Kumpfmüller et al. 2013
pAMYSSE Integration of genes into the amyE locus with SSE-cassette Kabisch et al. 2013a
pAMY-SSS Integration of genes into the amyE locus with SSS-cassette Kumpfmüller et al. 2013
pBB1366 Integration of genes in sacA locus with CmR Middleton and Hofmeister 2004
pDGICZ Source of cre operon and ZeoR Yan et al. 2008
pJET-lox-SSS Source of lox-SSS-cassette Kumpfmüller et al. 2013
pJK45 Integration of comS operon (Pspac) into sacA locus with Cm
R This study
pJK64 Reconstitution of genetic sfp defect with SSS-cassette This study
pJK64a Reconstitution of genetic sfp defect with lox-SSS-cassette This study
pJK93 Deletion of srfA operon with remaining KanR This study
pJK166 Integration of PacoA-esyn-TT7 into amyE locus This study
pJK179 Deletion of pksX operon This study
pJK191 Deletion of srfA operon This study
pJK195 Integration of cre operon (PxylA) into sacA locus with Zeo
R This study
pJK196 Integration of comS operon (Pspac) and cre operon (PxylA) into sacA locus with Zeo
R This study
pJK205 Insertion in lytC locus This study
pJK209 Deletion of spoIIGA This study
pJK226 Deletion of restriction and modification system (RM) This study
pJK210 Integration of genes in sacA locus with SpecR This study
pJK255 High-copy expression of PacoA-esyn-TT7 This study
pJK256 Substitution of comS operon (Pspac) and cre operon (PxylA) with Spec
R This study
pKE19 Source of srfA 5′-region with reconstituted comS gene Eppelmann et al. 2001
pKE27 Source of comS operon (Pspac) Eppelmann et al. 2001
pLytC Backbone for lytC deletion plasmid with SSC-cassette Kabisch et al. 2013b
pMSE3 High-copy E. coli/B. subtilis shuttle vector with KanR Silbersack et al. 2006
pSigL Backbone for pksX deletion plasmid with SSE-cassette Kabisch et al. 2013b
pSpoIIGA Backbone for spoIIGA deletion plasmid with SSS-cassette Kabisch et al. 2013b
pX Source of the xylA-promoter and xylR gene Kim et al. 1996
CmR chloramphenicol resistance cassette, EryR erythromycin resistance cassette, KanR kanamycin resistance cassette, SpecR spectinomycin resistance
cassette, ZeoR Zeocin resistance cassette, ss six-site, lox72 lox72 site, SSS SpecR flanked by two ss, SSE EryR flanked by two ss, SSC CmR flanked by
two ss, lox-SSS SSS surrounded by a lox71 and lox66 site
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plasmid. Obtained colonies were checked for haemolytic ac-
tivity on sheep blood agar plates indicating restored surfactin
production and hence PPTase activity due to a functional sfp
gene. After marker removal, one colony of the final strain
B. subtilis SZ4was chosen for genomic DNA isolation and the
chromosomal reconstitution of the sfp gene and the function-
ality of the esyn cluster were identified by means of PCR
followed by DNA sequencing.
The selected esyn-encoding strain B. subtilis BsSZ4
was cultivated at 37 °C in SB medium with 0.1 % acetoin as
the inducer. Supernatant and biomass were searched for the
presence of enniatin (enniatin B is the main product of ESYN
and, for reasons of simplicity, named enniatin) by means of
HPLC-ESI-mass spectrometry. This analytics rendered the
detection of enniatin adduct ions [M+H]+=640.4 Da, [M+
NH4]
+=657.4 Da and [M+Na]+=662.4 Da in the supernatant,
whereas only minute amounts were found in the biomass
(Fig. S3). Due to this repeated outcome of all fermentation
runs, the subsequent analyses were mainly performed with
culture supernatants.
The identity of enniatin was further corroborated by means
of HPLC/ESI-MS2 experiments (Fig. S4) upon identification
of characteristic masses of di- and tetrapeptidoles from
fragmentation reactions at the less stable ester bonds. In the
analytical assignment of secondary metabolites, we further
observed the molecular masses of bacillaene and surfactin,
previously identified from Bacillus species (Chen et al. 2007,
Fig. S5). In MRM measurements, minor amounts of enniatin
(∼0.4 μg/L) were detected.
In order to improve the enniatin production, variations in
the cultivation conditions like temperature, concentration of
the inductor acetoin and availability of required precursors in
the form of D-hydroxyisovalerate (D-Hiv) and L-valine (L-Val)
were tested. To minimize the metabolic burden for cells ex-
pressing a multi-enzyme of that size like enniatin synthetase
(Pfeifer and Khosla 2001), we lowered the incubation tem-
perature to slow down recombinant protein synthesis (Schein
1989). On the one hand, we chose 30 °C as well-known
growth temperature of the ubiquitous soil bacterium
B. subtilis. On the other hand, according to expression results,
we defined 18 °C as reasonable compromise between bacterial
growth and protein expression. Remarkably, lowering the
temperature resulted in higher enniatin synthesis (Fig. 2) com-
pared to 37 or 30 °C. Furthermore, also a doubling of the
cultivation duration led to a significantly increased enniatin
production.
Table 2 Strains used in this study
Strain Relevant genotype Reference
B. subtilis 168 Wild type, sfp0 Zeigler et al. 2008
B. subtilis ATCC 6051HGW Wild type, sfp+ Kabisch et al. 2013b
B. subtilis JK3 ΔsacA::(CmR, Pspac-comS, lacI) This study
B. subtilis JK13 ΔsacA::(ZeoR, Pspac-comS, lacI, PxylA-cre, xylR) This study
B. subtilis JK28 BsJK13+sfp+::lox72 This study
B. subtilis JK46 BsJK28+RM::lox72 This study
B. subtilis JK75 BsJK46+ΔsrfA::lox72 This study
B. subtilis JK76 BsJK75+ΔpksX::lox72 This study
B. subtilis JK77 BsJK76+ΔlytC::lox72 This study
B. subtilis JK78 BsJK77+ΔspoIIGA::lox72 This study
B. subtilis JK105 BsJK78+ΔamyE::lox72 This study
B. subtilis JK106 BsJK105+ΔsacA::SpecR This study
B. subtilis JK106 (pJK255) High-copy expression strain This study
B. subtilis SZ2 BsJK3+ΔamyE::(PacoA-esyn-TT7, ss) This study
B. subtilis SZ4 BsSZ2+sfp+::ss This study
B. subtilis SZ5 BsSZ4+ΔsacA::(ZeoR, Pspac-comS, lacI, PxylA-cre, xylR) This study
B. subtilis SZ6 BsSZ5+ΔlytC::lox72 This study
B. subtilis SZ7 BsSZ6+ΔspoIIGA::lox72 This study
B. subtilis SZ8 BsSZ7+ΔsacA::SpecR This study
B. subtilis SZ9 BsSZ7+ΔsrfA::lox72 This study
B. subtilis SZ10 BsSZ9+ΔsacA::SpecR This study
B. subtilis SZ11 BsSZ9+ΔpksX::lox72 This study
B. subtilis SZ12 BsSZ11+ΔsacA::SpecR This study
CmR chloramphenicol resistance cassette, SpecR spectinomycin resistance cassette, ZeoR Zeocin resistance cassette, ss six-site, lox72 lox72 site
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Enniatin production of a Bacillus strain carrying the esyn
gene and displaying only a basal synthesis of D-Hiv is depen-
dent on supplementation of this building block to the medium,
and this strain is therefore a dependent host. Based on the
absence of the native fungal D-hydroxyisovalerate dehydro-
genase, which catalyzes the transformation of 2-
ketoisovalerate (2-Kiv) to D-Hiv, the substrate of ESYN (Lee
et al. 1992) is missing in the recombinant host B. subtilis. Low
production of enniatin was observed without supplementa-
tion, indicating that there is some D-Hiv available, probably
in the undefined complex media ingredients like yeast extract.
Upon addition of various concentrations of D-Hiv, we were
able to enhance enniatin production significantly, although the
overall feeding of D-Hiv above 5 mM did not further influence
enniatin yields (Fig. 3a). In addition, requirements for L-Val in
primary metabolism, i.e. ribosomal synthesis of L-Val-rich
ESYN (7.8 %) and enniatin was compensated by feeding L-
Val. Hence, adding 5 mM of L-Val to the cultures after induc-
tion boosted the enniatin production of BsSZ4 by at least
another 10 % as determined by HPLC-MS (Fig. 3b).
In further experiments, we tested the inductor acetoin in
different concentrations in the range of 0.1, 0.5, 1.0 and 1.5 %
(v/v). We observed an increase of 10–20 % enniatin produc-
tion using 1.0 and 1.5 % acetoin for induction of ESYN
expression (Fig. S6). In contrast to the concentration range
of 0.1 and 0.5 % final acetoin, higher amounts of acetoin (1.0
and 1.5 %) are coupled to increased cell lysis (data not
shown). Therefore, for further experiments and optimization
regarding the genetic background of the enniatin producing
strain BsSZ4, we chose 0.1 % acetoin, 5 mM D-Hiv, no
additional L-Val (because no stringent necessity for enniatin
production) and 48 h cultivation time at 18 °C.
As mentioned above, the production of enniatin is accom-
panied by a surfactin and bacillaene synthesis, which is also
reflected by a high level of the proteins SrfAA and SrfAB
visible in a SDS-PAGE (Fig. S7) and confirmed by tryptic
digest of protein bands in LC-ESI-MS2 measurements
(data not shown). Since synthesis of unwanted protein appears
as an additional metabolic burden, we consequently consid-
ered inactivation of these clusters by gene deletion, which
ultimately could save equivalents of energy like ATP for
substrate activation, coenzyme A, precursors, cofactors and
Sfp capacity for posttranslational phosphopantetheinylation of
multienzymes. In order to optimize growth behaviour, we first
Fig. 2 Increased enniatin
production by shifting the
cultivation condition to lower
temperatures. Cultures of BsSZ4
were grown under the same
conditions with different
temperatures (18, 30 and 37 °C).
N=4
Fig. 3 Influence of precursor feeding on enniatin production. a Supple-
mentation with D-hydroxy isovalerate (D-Hiv): absence of D-Hiv in the
medium renders low enniatin yields in the supernatant. A concentration of
5 mM triples enniatin production. Higher amounts of D-Hiv have no
effect. N=4. b Supplementation with L-Val: in order to compensate L-
Val consumption during protein and peptide synthesis, 5 mM L-Val were
fed together with 5 mM D-Hiv to the cultures and raised enniatin produc-
tion by >10 %. N=2; thus, no median is shown
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inactivated genes involved in autolysis (lytC) and sporulation
(spoIIGA). Therefore, we stepwise engineered the BsSZ4
strain with an integrated single copy of esyn and observed a
surprisingly significant reduced enniatin synthesis in the
resulting BsSZ8 strain (Fig. 4a). An additional inactivation
of the surfactin gene cluster in BsSZ10 compensates these
losses and leads to an increase of around 20 % of enniatin
yield. As opposed to this, an additional inactivation of the
bacillaene cluster in BsSZ12 surprisingly led to significantly
decreased enniatin production (25 %) compared to BsSZ10.
The genetically modified strains revealed different growth
behaviours (Fig. 4b). Particularly the sporulation and lytC
deficient BsSZ8 strain showed decreased optical densities in
the time course measurements. The highest OD600 nm of 12.2
was observed for the best enniatin producing strain BsSZ10
being deficient in surfactin synthesis closely followed by the
parental strain BsJK28 (OD600 nm=11.4). The lowest produc-
tion of enniatin by BsSZ8 (with a lytC/spoIIGA inactivation)
correlates with the lowest cell density of OD600 nm=9.6 in
total. In the wake of BsSZ10 under optimized cultivation
conditions together with modification of the genetic back-
ground, we obtained a secretory production of 4.7 μg/L
enniatin.
We furthermore tested the effect of the cloning of the esyn
cluster into the high-copy plasmid pMSE3. The resulting
strain BsJK106 (pJK255), which possesses approximately
200 copies of the esyn gene (Fig. S8), produced the highest
yield of enniatin (Fig. 5). We quantified the extracts of super-
natant of BsJK106 cultures in comparison to an external
enniatin standard and measured yields of 1.1 mg/L enniatin
under optimized cultivation conditions. An additional gene
copy of the positive transcription factors sigL and acoR (Ali
et al. 2001; Kabisch et al. 2013b) did not lead to a further
enhanced enniatin production (data not shown).
Discussion
This contribution reports on a cellular system for heterologous
expression of a fungal, non-ribosomally synthesized peptide
based on the Gram-positive bacterium B. subtilis. To assess
the suitability of this expression host for heterologous NRPS
expression, the non-ribosomal peptide synthetase-encoding
gene esyn from the fungus F. oxysporum was used. This
choice was based on the natural capacity of B. subtilis for
the overproduction of the non-ribosomally synthesized
lipopeptides surfactin and plipastatin or the PKS/NRPS-
hybrid molecule bacillaene. As shown by the results of this
study, in B. subtilis, enniatin is actively exported, probably
using a native secondary metabolite transporter system,
whereas esyn expression in the Gram-negative expression host
E. coli leads to an exclusive intracellular accumulation of
enniatin (data not shown). Similar intracellular accumulation
of metabolites was observed in previous studies on heterolo-
gous expression in E. coli regarding the homologous
cyclooligomer depsipeptide synthetases, e.g. beauvericin syn-
thetase of Beauveria bassiana (Matthes et al. 2012) or
valinomycin synthetase produced by Streptomyces
tsusimaensis (Jaitzig et al. 2013).
Data of this study show that the cultivation temperature had
a significant effect on enniatin production. Lowering the tem-
perature causes decelerated cell growth due to lower metabol-
ic activity, which is a common method to avoid misfolding
and aggregation of heterologously expressed proteins (Schein
1989; Vasina and Baneyx 1997). To compensate for the
downregulated metabolism at 18 °C, the cultivation duration
was doubled, enabling a prolonged and thus increased
enniatin production.
In addition, feeding substrates which are building blocks of
the enniatin structure boosted enniatin synthesis.
Fig. 4 Engineering of the genetic background of the enniatin producing
strain B. subtilis BsSZ4. a Quantitative MRM analysis of secreted
enniatin of modified B. subtilis strains after cultivation for 48 h in SB
medium. N=4. b Growth curves (OD600nm) of engineered B. subtilis
strains during cultivation for 48 h in SB medium. N=1. BsJK28, parental
strain; BsSZ4, + esyn; BsSZ8, with a lytC/spoIIGA inactivation; BsSZ10,
deletion of the surfactin cluster; BsSZ12, with an additional inactivation
of bacillaene synthesis
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Concentrations of 5 mM of L-Val and D-Hiv are sufficient for
low expression of the cyclodepsipeptide. Higher feeding
amounts of L-Val could promote feedback reactions, which
might negatively influence the L-Val biosynthesis regulation
as observed for E. coli (Park et al. 2011). Supplementation
with 10 mM up to 15 mM D-Hiv could also result in oxidation
of dispensable D-Hiv through unspecific dehydrogenases from
pyruvate and amino acid metabolism, particularly those in-
volved in L-Val, L-Leu and L-Ile biosynthesis (Massey et al.
1976). Excessive addition of L-Val apparently is detrimental
and can cause overflow metabolism in the host organism
B. subtilis as well as limiting of L-Ile biosynthesis (Castillon
et al. 2011; Felice et al. 1977; Leavitt and Umbarger 1962).
For multi-copy expression of esyn, higher concentrations
of D-Hiv and L-Val might be required to saturate effective
enniatin production. Our data indicate that an increased con-
centration of the inductor molecule acetoin results in lower
cell densities revealing nearly the same amounts of enniatin
(data not shown). Reduced cell growth could be caused by
higher acetoin concentrations which lead to accumulation of
toxic diacetyl, catalyzed by non-enzymatic oxidations (López
et al. 1975). Therefore, induction of ESYN expression at
0.1 % acetoin seems to be most advantageous with regard to
cell-growth, protein synthesis and coupled enniatin produc-
tion (Fig. S6).
The negative effect caused by the deletion of the autolysis
gene lytC and the sporulation regulator gene spoIIGA
(Kabisch et al. 2013b) on the esyn-expressing strain
B. subtilis BsSZ8 was surprising. It could be speculated that
the spoIIGAmutation has an effect on the secretion capacity of
transporters for secondary metabolites. It is interesting to note
that the ABC transporters OppDF, YtrBE and EcsA are spe-
cifically induced during the sporulation process (Leskelä et al.
1999; Perego and Hoch 1996; Yoshida et al. 2000). For
YtrBE, a function in the uptake of the inductor acetoin has
been suggested. Thus, it is conceivable that a lower intracel-
lular inductor concentration is caused by a potential downreg-
ulation of YtrBE in a spoIIGA mutant. Further studies will be
required to elucidate the influence of this genetic background
on enniatin production in B. subtilis.
However, an additional deletion of the NRPS cluster
encoding the surfactin synthetase in strain BsSZ10 comple-
ments for above losses in production yields and results in an
enhanced enniatin production. On the one hand, the biosyn-
thesis of surfactin relies for a considerable part on the avail-
ability of L-Val as a precursor and the capacity for posttrans-
lational modification with Sfp, which could decrease the
Fig. 5 Extra-chromosomal multi-copy expression of esyn in B. subtilis.
Expression of the esyn gene on the multi-copy plasmid pJK255 (with
∼200 copies) in BsJK106 in comparison to BsSZ10 leads to 130-fold
increased enniatin level in the supernatant. N=4
Fig. 6 Comparison of the overall
optimization of enniatin
production in the heterologous
producer B. subtilis. Quantitative
HPLC-MRM mass spectrometric
analysis of crude culture
supernatant extracts of BsSZ4 and
BsSZ10 as well as BsJK106
shows enhanced enniatin
production as a result of a
combination of cultivation
optimization, genetic
modification and high-copy
expression of heterologously
expressed ESYN
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ESYN productivity. Therefore, a deletion of the srfA-cluster
might lead to an accumulation of the resources available for
enniatin synthesis. On the other hand, this cluster contains a
beneficial type II thioesterase SrfAD for regeneration of
misprimed nonribosomal peptide synthetase (Schwarzer
et al. 2002). Consequently, a co-expression of this type II
thioesterase could be advantageous also for the enniatin pro-
duction. We have addressed not only the gene inactivation of
the surfactin-relevant cluster but also the pksX cluster of the
mixed PKS/NRPS secondary metabolite bacillaene (BsSZ12).
In this case, the secondary metabolite was identified by means
of ESI-mass spectrometry but no high expression level of the
synthetase was detected on the protein level in SDS gels
(Fig. S7). The slightly negative effect on enniatin concentra-
tion after inactivation of the pksX cluster was quite unexpected
(Fig. 4a) and suggests that its inactivation has no direct influ-
ence on the availability of precursors or resources of enniatin
production.
The highest yield of enniatin secreted into the supernatant
was found for strain BsJK106 with the esyn-encoding multi-
copy plasmid pJK255. This optimized host vector system,
which originates from strain BsSZ12 and comprises gene
deletions of the srfA and pksX clusters, is based on the high-
copy plasmid pMSE3. In comparison to other plasmids tested,
plasmid pMSE3 is distinguished (Fig. S8) by structural and
segregational stability (Silbersack et al. 2006; Swinfield et al.
1991) with ∼200–250 copies per cell. Despite the metabolic
burden of replication and protein synthesis by this high-copy
plasmid number, as indicated by lower cell densities, enniatin
synthesis significantly increased by ∼50% (Fig. 5). It could be
concluded that the deletion of energy- and metabolic
precursor-consuming clusters maybe useful for multi-copy
expression of ESYN in strain BsJK106. The ultimate strain
of this study, BsJK106 (pJK255), produces 1.1 mg/L enniatin
(Fig. 6). We assume that there is further potential for optimi-
zation of the secretory enniatin production in B. subtilis. This
could include classical strain evolvement by mutagenesis as
well as the development of suitable fed-batch cultivations
including the adjustment of feeding or synthesis of the build-
ing blocks D-Hiv and L-Val. First additional optimization steps
by overexpressing the appropriate transcription factors AcoR
and SigL of the acoA promoter resulted in an almost complete
collapse of enniatin production and cell growth (data not
shown). Thus, a balanced ratio of gene copies, transcription
and translation regulation as well as concentrations of precur-
sors will be required. For the generation of an autonomous
B. subtilis strain producing enniatin without additional D-Hiv
feeding, exploitation of the gene coding for the D-
hydroxyisovalerate dehydrogenase of F. oxysporum (Lee
et al. 1992) could be considered by chromosomal integration
into strain BsJK106.
To our knowledge, this is the first study to examine the
heterologous expression of a NRPS of eukaryotic origin in the
Gram-positive bacterial production host B. subtilis. The ap-
proach is considered to have a promising potential being
applicable to generate enniatin easily in an economic contin-
uous fermentation process since the entire cyclodepsipeptide
is secreted into the medium. Furthermore, this heterologous
production of enniatin can also be used for precursor-directed
biosynthesis (Feifel et al. 2007; Krause et al. 2001; Matthes
et al. 2012; Müller et al. 2009) of new interesting derivatives
providing additional or improved bioactivity by feeding and
incorporation of α-hydroxyl carboxylic acid derivatives.
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